The use of mass spectrometry imaging to predict treatment response of patient-derived xenograft models of triple-negative breast cancer.

In recent years, mass spectrometry imaging (MSI) has been shown to be a promising technique in oncology. The effective application of MSI, however, is hampered by the complexity of the generated data. Bioinformatic approaches that reduce the complexity of these data are needed for the effective use in a (bio)medical setting. This holds especially for the analysis of tissue microarrays (TMA), which consist of hundreds of small tissue cores. Here we present an approach that combines MSI on tissue microarrays with principal component linear discriminant analysis (PCA-LDA) to predict treatment response. The feasibility of such an approach was evaluated on a set of patient-derived xenograft models of triple-negative breast cancer (TNBC). PCA-LDA was used to classify TNBC tumor tissues based on the proteomic information obtained with matrix-assisted laser desorption ionization (MALDI) MSI from the TMA surface. Classifiers based on two different tissue microarrays from the same tumor models showed overall classification accuracies between 59 and 77%, as determined by cross-validation. Reproducibility tests revealed that the two models were similar. A clear effect of intratumor heterogeneity of the classification scores was observed. These results demonstrate that the analysis of MALDI-MSI data by PCA-LDA is a valuable approach for the classification of treatment response and tumor heterogeneity in breast cancer.

[1]  Z. Szallasi,et al.  Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  André M Deelder,et al.  Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity , 2010, The Journal of pathology.

[3]  Stefan K. Maier,et al.  Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria , 2013, The Journal of pathology.

[4]  Liam A. McDonnell,et al.  Multiple Statistical Analysis Techniques Corroborate Intratumor Heterogeneity in Imaging Mass Spectrometry Datasets of Myxofibrosarcoma , 2011, PloS one.

[5]  Wolfgang Heller,et al.  Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.

[6]  Arend Heerschap,et al.  A chemometric approach for brain tumor classification using magnetic resonance imaging and spectroscopy. , 2003, Analytical chemistry.

[7]  Sören-Oliver Deininger,et al.  MALDI imaging combined with hierarchical clustering as a new tool for the interpretation of complex human cancers. , 2008, Journal of proteome research.

[8]  Richard M Caprioli,et al.  Early Changes in Protein Expression Detected by Mass Spectrometry Predict Tumor Response to Molecular Therapeutics , 2004, Cancer Research.

[9]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[10]  Gert B. Eijkel,et al.  Time-of-flight secondary ion mass spectrometry-based molecular distribution distinguishing healthy and osteoarthritic human cartilage. , 2012, Analytical chemistry.

[11]  Gert B. Eijkel,et al.  Matrix-assisted laser desorption ionization-imaging mass spectrometry: a new methodology to study human osteoarthritic cartilage. , 2013, Arthritis and rheumatism.

[12]  R. Caprioli,et al.  Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation , 2010, Clinical Cancer Research.

[13]  A. Smilde,et al.  How to distinguish healthy from diseased? Classification strategy for mass spectrometry‐based clinical proteomics , 2007, Proteomics.

[14]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[15]  Horst Zitzelsberger,et al.  Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging. , 2012, Journal of proteome research.

[16]  R. Casadonte,et al.  Proteomic analysis of formalin-fixed paraffin-embedded tissue by MALDI imaging mass spectrometry , 2011, Nature Protocols.

[17]  M. Clench,et al.  Novel molecular tumour classification using MALDI–mass spectrometry imaging of tissue micro-array , 2010, Analytical and bioanalytical chemistry.

[18]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[19]  Pierre P Massion,et al.  High‐throughput proteomic analysis of formalin‐fixed paraffin‐embedded tissue microarrays using MALDI imaging mass spectrometry , 2008, Proteomics.

[20]  Gert B. Eijkel,et al.  Correlating MALDI and SIMS imaging mass spectrometric datasets of biological tissue surfaces , 2009 .

[21]  P. G. Kistemaker,et al.  Discriminant analysis by double stage principal component analysis , 1983 .

[22]  Detlev Suckau,et al.  Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. , 2010, Journal of proteome research.

[23]  E. Raso,et al.  Analysis of colorectal adenocarcinoma tissue by desorption electrospray ionization mass spectrometric imaging , 2012, Analytical and Bioanalytical Chemistry.

[24]  Ara Darzi,et al.  Chemo-informatic strategy for imaging mass spectrometry-based hyperspectral profiling of lipid signatures in colorectal cancer , 2014, Proceedings of the National Academy of Sciences.